Price movement over the last 24 hours
Agilent Technologies Inc vs Cigna Corp — how do they compare? Agilent Technologies Inc trades at $128.45 (market cap $37.04B), while Cigna Corp trades at $289.36 (market cap $75.82B). The key difference: Cigna Corp is far larger — about 2× Agilent Technologies Inc's market cap, and Cigna Corp pays the higher dividend (2.18%). Which is the better fit depends on your goals.
| A | CI | |
|---|---|---|
Market Cap | $37.04B | $75.82B |
Sector | Health | Health |
52-Week High | $157.20 | $312.00 |
52-Week Low | $110.24 | $244.41 |
Enterprise Value | $38.59B | $98.92B |
Dividend Yield | 0.78% | 2.18% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Cigna (CI) trades at $286.62, down 0.4% on the day, with a neutral technical signal. The stock shows strong fundamentals with a low P/E of 11.95 and consistent earnings beats, including Q1 2026 EPS of $7.79 versus $7.60 expected. Revenue grew to $273.85B in 2025, and the company is expanding into AI-driven healthcare services, as highlighted by recent news of Evernorth's Pharmacy Forward initiative (PRNewswire, 2026-07-01).
The outlook is positive given analyst consensus with a $338.91 price target and 73.68% buy ratings. Key risks include regulatory challenges, such as the Tennessee prescription access lawsuit (Reuters, 2026-06-12), and volatility in medical cost trends. The stock offers value with a dividend yield supported by a recent $1.56 payout, but investors should monitor execution in specialty pharmacy expansion.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →